1. Home
  2. FOXX vs VCEL Comparison

FOXX vs VCEL Comparison

Compare FOXX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FOXX

Foxx Development Holdings Inc.

N/A

Current Price

$2.85

Market Cap

35.6M

Sector

N/A

ML Signal

N/A

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$46.71

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
VCEL
Founded
2017
1989
Country
United States
United States
Employees
25
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
2.4B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FOXX
VCEL
Price
$2.85
$46.71
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$57.75
AVG Volume (30 Days)
32.9K
704.3K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.00
EPS
N/A
N/A
Revenue
N/A
$276,259,000.00
Revenue This Year
N/A
$19.40
Revenue Next Year
N/A
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.45
52 Week Low
$1.71
$28.95
52 Week High
$8.70
$48.75

Technical Indicators

Market Signals
Indicator
FOXX
VCEL
Relative Strength Index (RSI) 40.35 62.42
Support Level $2.69 $32.47
Resistance Level $4.88 N/A
Average True Range (ATR) 0.29 1.81
MACD 0.01 -0.21
Stochastic Oscillator 16.67 60.92

Price Performance

Historical Comparison
FOXX
VCEL

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: